/images/ppid_59c68470-image-176241505878480812.webp)
/images/ppid_a911dc6a-image-177105956122469810.webp)
/images/ppid_a911dc6a-image-177105952513238219.webp)
What is the story about?
Shares of Indoco Remedies Ltd. gained on Thursday, November 6, after the company witnessed a slight improvement in earnings in the second quarter.
The company's net loss improved to ₹8 crore from ₹9.6 crore in the September quarter last year.
Its revenue increased 12% to ₹485 crore from ₹433 crore in the srecond quarter last fiscal.
Indoco Remedies' earnings before interest, tax, depreciation and amortisation (EBITDA) increased 6.6% in the September quarter to ₹43.4 crore from ₹41 crore last year.
Its margins contracted marginally to 9% from 9.4% in the year-ago period.
Indoco Remedies had reported a net loss of ₹35.6 crore in the June quarter of the financial year 2026 compared to a net profit of ₹2.6 crore in the same period of the previous year.
Its revenue increased 1.5% to ₹438 crore from 431.5 crore in the first quarter of FY25.
The company's EBITDA declined 62.8% to ₹17.8 crore in the first quarter from ₹47.8 crore in the previous year.
As a result, its EBITDA margin had contracted to 4.06% in the first quarter from 11.08% in the year-ago period.
Shares of Indoco Remedies were up 1.5% at 275 crore around 11.55 am on Thursday. The stock has gained 14.4% in the last six months but has declined nearly 18% this year, so far.
Also Read: Stock Crash: Epack Durables shares tank 10% after Q2 loss; Higher expenses weigh
The company's net loss improved to ₹8 crore from ₹9.6 crore in the September quarter last year.
Its revenue increased 12% to ₹485 crore from ₹433 crore in the srecond quarter last fiscal.
Indoco Remedies' earnings before interest, tax, depreciation and amortisation (EBITDA) increased 6.6% in the September quarter to ₹43.4 crore from ₹41 crore last year.
Its margins contracted marginally to 9% from 9.4% in the year-ago period.
Q1 performance
Indoco Remedies had reported a net loss of ₹35.6 crore in the June quarter of the financial year 2026 compared to a net profit of ₹2.6 crore in the same period of the previous year.
Its revenue increased 1.5% to ₹438 crore from 431.5 crore in the first quarter of FY25.
The company's EBITDA declined 62.8% to ₹17.8 crore in the first quarter from ₹47.8 crore in the previous year.
As a result, its EBITDA margin had contracted to 4.06% in the first quarter from 11.08% in the year-ago period.
Shares of Indoco Remedies were up 1.5% at 275 crore around 11.55 am on Thursday. The stock has gained 14.4% in the last six months but has declined nearly 18% this year, so far.
Also Read: Stock Crash: Epack Durables shares tank 10% after Q2 loss; Higher expenses weigh
